Top 50 Ai For Genomics in Asia

GENOBOTICS AI provides a cloud‑native platform that applies deep‑learning models to automatically annotate genomic variants and predict their therapeutic relevance. Users upload standard formats (VCF, BAM, FASTQ) and receive batch‑processed results within minutes via RESTful APIs or an interactive dashboard, with end‑to‑end encryption and HIPAA/GDPR compliance for pharmaceutical, biotech, and academic precision‑medicine teams.

OneCell.Ai provides an AI‑enhanced single‑cell multi‑omics platform that integrates DNA, RNA, and protein analysis from tissue or liquid biopsies into a single assay, delivering real‑time, actionable genomic insights for cancer care. Its suite of branded tests—including OncoIndx®, OncoIndx® Prime+, OncoRisk®, OncoTarget®, and OncoHRD®—offers comprehensive profiling of somatic and germline mutations, gene fusions, pharmacogenomics, and HRD scores to support targeted therapy selection, immunotherapy eligibility, resistance monitoring, and clinical‑trial matching.

MEDHINI is a generative AI-powered software platform that provides genomics-based multimodal solutions for healthcare diagnostics, focusing on areas such as antimicrobial resistance and virtual clinical trials. The platform enhances diagnostic accuracy and accessibility in pulmonology, neurology, nephrology, cardiology, and oncology, addressing the need for affordable healthcare solutions with measurable social impact.

1Cell provides an AI-powered single‑cell liquid biopsy platform that isolates circulating tumor cells and generates multi‑omics profiles in real time. The system combines high‑throughput cell capture hardware with machine‑learning analytics to deliver molecular signatures for early cancer detection, therapy response prediction, and disease monitoring.

3BIGS utilizes bio big data and AI-driven platforms to analyze next-generation sequencing (NGS) data, identifying patterns, mutations, and biomarkers for drug discovery and healthcare insights. The company addresses the challenge of extracting actionable information from vast biological datasets, accelerating the development of targeted therapies and improving patient outcomes.

Engine Biosciences uses machine learning and high‑throughput biology to map genetic interactions in complex disease networks, identifying therapeutic targets and biomarkers for defined patient groups. It translates these insights into precision medicines and companion diagnostics, focusing on solid tumor indications. The company also offers its platform and assets for partnership to accelerate R&D and clinical development.

BluMaiden uses AI‑driven computational chemistry to convert metagenomic and multi‑omics data into predicted structures of human‑derived natural products, uncovering the hidden “chemical dark matter” of bioactive compounds. Its platform integrates genome‑to‑molecule translation, scaffold prediction, and ligand‑target interaction modeling to prioritize and optimize evolutionarily refined drug candidates for pharmaceutical and biotech development.

Helix integrates genomic data into healthcare systems, enabling health organizations to utilize population genomics for personalized diagnosis, treatment, and prevention. By providing actionable genetic insights, Helix enhances patient outcomes and reduces costs across medical research and clinical care.

4baseCare develops precision oncology solutions utilizing next-generation sequencing and comprehensive genomic profiling to identify specific cancer mutations in patients. Their technology addresses the need for personalized treatment options by providing tailored insights that enhance therapeutic decision-making for cancer care in the Indian population.

ZipBio uses generative AI to design compact, multispecific protein therapeutics called Zip® drugs, enabling the creation of novel biologics that are difficult to produce with traditional methods. These smart proteins target unmet medical needs across various disease areas, and the company monetizes its pipeline through licensing, partnerships, and eventual product sales. The platform aims to accelerate drug development by compressing biological complexity into engineered therapeutic candidates.

Algorithmic Biologics develops a software platform that enhances molecular testing workflows through advanced computational applications, including compression algorithms for next-generation sequencing. This technology significantly reduces library preparation costs by over 60%, making molecular diagnostics more accessible and efficient for healthcare providers.

UMAMI Bioworks develops a scalable platform for cultivating seafood from endangered, threatened, or protected species using genomics, stem cell biology, and machine learning. This approach addresses the critical issue of overfishing and oceanic degradation by providing a sustainable alternative to traditional fishing methods.

The startup develops RNA fragmentomics technology for real-time disease detection, enhancing diagnosis and treatment in cancer and infectious diseases. Their platform facilitates biomarker discovery, liquid biopsy, and single-cell analysis, enabling healthcare providers to improve patient outcomes through precise RNA-based diagnostics.

Provides genetic testing services using next-generation sequencing and proprietary algorithms to detect hereditary diseases, cancer mutations, and genetic disorders. These tests enable early diagnosis, personalized treatment plans, and risk assessment, improving health outcomes for patients in prenatal, oncology, and chronic disease contexts.

PrognomiQ develops transformative test products focused on the early detection and treatment of cancer and other complex diseases. The company achieves this by generating proprietary proteomic data at high volume and depth. This proteomic information is integrated with genomic and metabolomic data to create powerful multi-omics insights for clinical applications.

Eleven Therapeutics utilizes synthetic chemistry and AI algorithms to develop RNA therapeutics that optimize safety, efficiency, and duration of effect. Their platform maps the vast chemical space of RNA molecules, addressing the need for precise and effective therapeutic solutions in the rapidly evolving field of RNA-based medicine.

Cambrian Bioworks develops nucleic acid extraction technologies and tools for molecular diagnostics and life science research, enhancing workflow efficiency in applications such as sequencing and genotyping. Their products, including the Manta system, address the complexities of sample preparation and handling, making genomics more accessible and affordable.

Igentify Ltd offers a digital platform that streamlines genomic workflows, enabling patients, laboratories, and healthcare providers to access and interpret genetic information securely. This solution addresses the challenge of inefficient genetic data management, enhancing the effectiveness of preventive healthcare services.

Biomica develops microbiome-based therapeutics using a proprietary computational platform that integrates metagenomics sequencing and AI to identify optimal microbial candidates for treating cancer, immune-mediated, and infectious diseases. The company addresses the challenge of unmet medical needs by maximizing therapeutic efficacy while minimizing adverse effects through carefully curated microbial consortia.

Geneyx provides DNA and RNA data analysis and interpretation for whole genome sequencing (WGS), whole exome sequencing (WES), gene panels, and microarrays, enabling rapid transformation of raw genetic data into clinical reports. The platform enhances diagnostic accuracy and efficiency, aiming to eliminate undiagnosed diseases by increasing the diagnostic yield and reducing turnaround times for genetic testing.

MGI Tech develops genetic sequencers and lab automation tools that enhance genomic analysis and streamline sample preparation processes in life sciences. Their technology addresses the need for efficient, high-throughput sequencing and data management, enabling precise diagnostics and research in healthcare and agriculture.

This startup develops a platform that integrates advanced genomic technologies for diagnostics, prognostics, and therapeutic development. It offers genetic testing and counseling to diagnose and treat rare diseases, enabling personalized care for patients.

Identifai Genetics provides an early‑stage, non‑invasive prenatal screening that analyzes fetal cell‑free DNA from a simple maternal blood draw in the first trimester. Their proprietary bioinformatics pipeline digitally isolates fetal DNA from the mixed maternal‑fetal sample, reconstructs the fetal genome at high resolution, and detects a wide range of genetic conditions—from single‑gene mutations to chromosomal anomalies—delivering a comprehensive clinical report for obstetricians and genetics specialists.

Novo Genomics offers comprehensive genomic and multi-omics analysis services to provide personalized health and wellness insights. They make precision medicine accessible through genetic testing, oncology diagnostics, pharmacogenomics, prenatal screening, and rare disease diagnosis. Their offerings support individuals, clinicians, and researchers in improving health outcomes and advancing genomic studies.

The startup develops a genotyping and sequencing platform that translates genetic data into clinical applications, enabling healthcare providers to make informed treatment decisions. This technology enhances patient care and biomedical research by improving the understanding and management of diseases.

This startup offers whole genome sequencing and genetic testing services to identify health risks and inform personalized medicine. They provide genetic counseling and bioinformatics tools to patients and healthcare providers for accurate genetic analysis.

Zene is a genome data analysis platform that offers high-precision genomic analysis services using saliva samples to provide individuals with insights into their genetic traits. The platform also supports health insurance organizations by delivering actionable genomic information to reduce medical costs and enhance employee health management.

CrisprBits develops intelligent molecular platforms powered by CRISPR technology for applications across healthcare, food safety, and sustainability. The company offers scalable solutions including PathCrisp for rapid diagnostics, EdiCrisp for precision genome engineering, and CurieCrisp for preclinical disease modeling. These platforms aim to deliver cost-effective innovations in diagnostics, gene editing, and strain engineering sectors.

MNDL Bio utilizes AI-driven computational models to optimize gene expression for recombinant protein production, significantly enhancing yield and reducing costs. The platform replaces traditional trial-and-error methods with precise, data-driven strain engineering, enabling faster time-to-market and improved sustainability in biotech and foodtech applications.

KANAPH Therapeutics uses a genomics‑driven platform to discover disease signatures and translate them into next‑generation therapeutics for solid‑tumor oncology and ocular diseases. The company integrates human genome analysis with protein engineering to create bispecific antibodies, synthetic small‑molecule pipelines, and advanced ADCs featuring hydrophilic linkers and customizable payloads, delivering highly selective candidates from target validation through preclinical and early clinical stages.

This deep tech company leverages digital biomarkers, blood biochemicals, genomics markers, machine learning, and deep learning to provide personalized, evidence-based Ayurvedic health and wellness solutions. It addresses the lack of data-driven frameworks in traditional Ayurveda, enabling P5 medicine through a scientific approach.

Vision Medicals specializes in gene technology and precision medicine to enhance patient-specific treatment strategies. The company focuses on utilizing genomic data to improve diagnostic accuracy and tailor therapies for genetic disorders, ultimately increasing treatment efficacy.

GenomiCare Biotechnology provides precision cancer medicine services through genomic profiling and targeted therapy recommendations. The company addresses the challenge of ineffective cancer treatments by offering personalized treatment plans based on individual genetic mutations.

Auristone provides epigenomics‑driven molecular profiling for cancer, offering the EPI‑CALL™ test that combines RNA‑Seq and epigenomic analysis to deliver actionable insights such as immune‑cell profiling, tumor microenvironment classification, and gene‑fusion detection for clinicians. For researchers, the Signomax™ platform delivers end‑to‑end RNA‑Seq and ultra‑low‑input Nano‑ChIP‑Seq services with customizable bioinformatics pipelines, leveraging proprietary algorithms trained on Asian epigenomic datasets to accelerate biomarker discovery and precision medicine.

The startup provides genomic reports tailored for the Indian population by integrating genomic, physiological, and physical data through machine learning algorithms. This approach enables individuals to understand their genetic predispositions and make informed decisions about their diet and lifestyle to mitigate the risk of lifestyle and clinical disorders.

The startup develops genome analysis technology that enables contract testing and analysis services to detect minute quantities of bacteria in embryos by examining their genes and chromosomes. This technology helps identify genetic abnormalities before pregnancy, thereby alleviating physical and mental burdens for women.

Genz develops AI algorithms for genomic data analysis to facilitate personalized treatment plans for women with breast cancer. By leveraging advanced data analytics, the company aims to enhance the precision of therapeutic interventions tailored to individual genetic profiles.

Leucine Rich Bio is South Asia's first microbiome-focused genomics company, specializing in preventive healthcare and precision medicine through advanced microbiome analysis. The company provides insights that enable personalized health interventions, addressing the need for tailored healthcare solutions based on individual microbiome profiles.

This company operates an AI-powered marketplace connecting users with personalized wellness solutions based on their genetic profile and stated goals. Users input health challenges or lifestyle objectives, and the platform matches them with relevant vendors and products. The service aims to facilitate living life by design through data-driven wellness recommendations.

ACT Genomics provides genomic profiling services that deliver actionable insights on biomarkers and genomic alterations to tailor cancer treatment plans for patients. By utilizing precision testing, the company enhances treatment selection and clinical trial matching, improving patient outcomes in oncology.

GeneStory provides comprehensive genetic sequencing and analysis services utilizing proprietary algorithms and a reference database of Vietnamese genomes. The company delivers personalized health reports covering disease risk, drug response (pharmacogenomics), nutrition, and physical potential. This data enables individuals to optimize their lifestyle, nutrition, and preventative healthcare strategies.

Psifas is developing a platform that integrates longitudinal medical records with whole genome sequencing data to facilitate targeted medical research. This approach enables early disease detection and intervention, improving health outcomes by providing researchers with comprehensive, anonymized datasets for analysis.

This company develops HeartDyno, a human cardiac tissue discovery platform, to decode heart function and identify novel drug targets for precision cardiology. The platform integrates functional data with an in silico system, Tempo.ai, to analyze multi-omics data and predict drug safety and efficacy. This engine maps new targets, therapies, and patient populations to advance therapeutic assets for cardiovascular disease.

Regene Genomics provides predictive diagnostics through genetic testing, enabling individuals to understand their genetic predispositions and make informed health decisions. The company focuses on delivering accurate test results while ensuring data privacy and fostering transparent communication with clients.

BathGenBio utilizes artificial intelligence to analyze extensive biobank data, including genomic and clinical information, to identify novel biomarkers and optimize drug discovery processes. The platform addresses the challenges of precision medicine by enhancing target discovery, drug response prediction, and drug repurposing for medical institutions and biotechnology companies.

Amwise Diagnostic specializes in precision medicine technology that utilizes genomic profiling and biomarker analysis to tailor cancer treatment plans for individual patients. This approach enhances treatment efficacy and minimizes adverse effects by ensuring therapies are specifically matched to the unique genetic makeup of each tumor.

This startup provides an AI-powered blockchain platform for decentralized science, specifically focused on genomics. It offers researchers access to clean, labeled, and organized genetic profiles, accelerating the development of personalized, data-driven medical solutions and reducing time-to-market for genomics-based AI applications.

Foresee Genomics provides comprehensive next-generation sequencing (NGS) solutions, including protocols, reagents, and bioinformatics tools, to make high-accuracy genomic analysis accessible to smaller laboratories. Their technology enables labs to perform rapid, accurate diagnostics with minimal investment and small sample requirements. This accessibility accelerates timely genomic testing, supporting precision medicine and enhancing patient care outcomes.

ComputeGenomics provides specialized, high-performance computing (HPC) platforms tailored for accelerating large-scale genomics data analysis. The platform utilizes CPU/GPU-based approaches to rapidly process complex genomic studies such as variant calling, genotyping, and single-cell analysis. They deliver integrated, on-premise hardware solutions with scalable storage and dedicated administrative support for secure data management.

This startup provides a bioinformatics platform that analyzes single-cell genomic data to help researchers understand disease mechanisms. It offers accessible, expert data analysis tools, enabling clients to advance genomic research for personalized medicine.